Gentile, Francesco
Maranzano, Alessio
Verde, Federico
Bettoni, Veronica
Colombo, Eleonora
Doretti, Alberto
Olivero, Marco
Scheveger, Francesco
Colombrita, Claudia
Bulgarelli, Ilaria
Spinelli, Edoardo Gioele
Torresani, Erminio
Messina, Stefano
Maderna, Luca
Agosta, Federica
Morelli, Claudia
Filippi, Massimo
Silani, Vincenzo
Ticozzi, Nicola http://orcid.org/0000-0001-5963-7426
Funding for this research was provided by:
Università degli Studi di Milano
Article History
Received: 19 July 2023
Revised: 18 September 2023
Accepted: 19 September 2023
First Online: 6 October 2023
Declarations
:
: F. Gentile, A. Maranzano, F. Verde, V. Bettoni, E. Colombo, A. Doretti, M. Olivero, F. Scheveger, C. Colombrita, I. Bulgarelli, E.G. Spinelli, E. Torresani, S. Messina, L. Maderna and C. Morelli report no disclosure. F. Agosta is Section Editor of NeuroImage: Clinical; has received speaker honoraria from Biogen Idec, Roche, Zambon and Italfarmaco; and receives or has received research supports from the Italian Ministry of Health, AriSLA (Fondazione Italiana di Ricerca per la SLA), the European Research Council and the Foundation Research on Alzheimer Disease. M. Filippi is Editor in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Associate Editor of Radiology, and Associate Editor of Neurological Sciences; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). V. Silani received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, LiquidWeb, Srl and Novartis Pharma AG. He receives or he has received research support from the Italian Ministry of Health, AriSla, and E-Rare Joint Translational Call. He is on. the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemproal Degeneration, European Neurology, American Journal of Neurodegenerative Disease and Frontiers in Neurology. N. Ticozzi received compensation for consulting services from Amylyx Pharmaceutical, Biogen, Italfarmaco and Zambon Biotech SA. He received research funding from the Italian Ministry of Health and AriSLA. He is associate editor of Frontiers in Aging Neuroscience.
: We received approval for this study from the Ethics Committee of Istituto Auxologico Italiano IRCCS (2021_05_18_04).